Abstract
In many countries, HIV infections among MSM (MSMHIV) are closely monitored, and updated epidemiological reports are made available annually, yet the true prevalence of MSMHIV can be masked for areas with small population density or lack of data. Therefore, this study aimed to investigate the feasibility of small area estimation with a Bayesian approach to improve HIV surveillance. Data from the European MSM Internet Survey 2017 (EMIS-2017, Dutch subsample, n=3,459) and the Dutch survey ‘Men & Sexuality-2018’ (SMS-2018, n=5,653) were utilized in this study. We first applied a frequentist calculation to compare the observed relative risk of MSMHIV per Public Health Services (GGD) region in the Netherlands. We then applied a Bayesian spatial analysis and ecological regression to account for variance due to space and determinants associated with HIV among MSM to obtain more robust estimates. Results of the prevalence and risk estimations from EMIS-2017 and SMS-2018 converged with minor differences. Both estimations confirmed that the risk of MSMHIV is heterogenous across the Netherlands with some GGD regions, such as GGD Amsterdam [RR=1.21 (95% credible interval 1.05-1.38) by EMIS-2017; RR=1.39 (1.14-1.68) by SMS-2018], having a higher-than-average risk. Results from our ecological regression modelling revealed significant regional determinants which can impact on the risk for MSMHIV. In sum, our Bayesian approach to assess the risk of HIV among MSM was able to close data gaps and provide more robust prevalence and risk estimations. It is feasible and directly applicable for future HIV surveillance as a statistical adjustment tool.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for EMIS-2017 survey was obtained from the Observational Research Ethics Committee at the London School of Hygiene & Tropical Medicine (review reference 14421 /RR/8805). Ethical approval for SMS-2018 survey was obtained from the Ethics Committee of the Faculty of Social and Behavioural Sciences, Utrecht University (FETC17-131).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
